OICR is a collaborative, not-for-profit research institute accelerating the development of cancer research discoveries for patients around the world.
Location: Canada, Ontario
Employees: 201-500
Founded date: 2005
Investors 1
| Date | Name | Website |
| - | Fight Agai... | facit.ca |
Mentions in press and media 7
| Date | Title | Description |
| 23.05.2024 | Providence and Ontario Institute for Cancer Research (OICR) partnering to discover and develop mRNA therapeutics | CALGARY, AB and TORONTO, May 23, 2024 /PRNewswire/ -- Providence Therapeutic Holdings Inc. ("Providence"), a messenger RNA (mRNA) and lipid nanoparticle platform company engaged in the development of vaccines and therapeutics, and... |
| 19.08.2017 | Four intriguing biopharma developments this week | Alzeca Biosciences in Houston closed an $11 million Series A round to advance an imaging technology for early diagnosis of Alzheimer’s disease it regards as a cheaper alternative to PET scans. Nanoparticles bind to amyloid plaque in the bra... |
| 14.07.2011 | DVS Sciences Completes $14.6M Series A Financing | DVS Sciences, a Toronto, Canada-based an analytical equipment and reagents development company, has completed a $14.6m Series A financing. The round was led by 5AM Ventures, with particiption from Mohr Davidow Ventures, Pfizer Venture Inves... |
| 12.10.2010 | Privacy Analytics Receives Equity Investment from OICR | Privacy Analytics Inc., a Toronto, CA-based company that is developing a software platform to help organizations such as health centers disclose detailed disease and treatment data without compromising individual privacy, has received an an... |
| - | Four intriguing biopharma developments this week | Even in the dog days of summer, it was hardly a dull week in the world of biopharma. Amidst the fallout from President Trump’s comments during and following the white supremacist rally in Charlottesville spurred an exodus from his manufactu... |
| - | Fusion Pharmaceuticals Completes Oversubscribed Series A Financing Totaling $46 Million USD to Develop Targeted Alpha Therapeutics | HAMILTON, ONTARIO, September 25, 2017 – Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced it has completed a second closing of its Se... |
| - | Fusion Pharmaceuticals Launches with a $25M USD Series A Financing to Develop Targeted Radiotherapeutics as Cancer Treatments | HAMILTON ONTARIO, February 23, 2017 – Fusion Pharmaceuticals, a newly formed biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced the closing of a $25 million Series A financing... |